Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6361 AL 6375

REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state

Panza F, Frisardi V, Imbimbo BP, Capurso C, Logroscino G, Sancarlo D, Seripa D, Vendemiale G, Pilotto A, Solfrizzi V.

CNS Neurosci Ther. 2010 Oct;16(5):272-84. doi: 10.1111/j.1755-5949.2010.00164.x. Epub 2010 Jun 16.

Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease?

Martorana A, Esposito Z, Koch G.

CNS Neurosci Ther. 2010 Aug;16(4):235-45. doi: 10.1111/j.1755-5949.2010.00175.x. Epub 2010 Apr 16.

Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease

Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stüve O, Rosenberg RN.

Vaccine. 2010 Jul 19;28(32):5280-7. doi: 10.1016/j.vaccine.2010.05.054. Epub 2010 Jun 4.

Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials

McArthur RA, Gray J, Schreiber R.

Curr Opin Investig Drugs. 2010 Jul;11(7):740-60.

Antioxidant approaches for the treatment of Alzheimer's disease

Lee HP, Zhu X, Casadesus G, Castellani RJ, Nunomura A, Smith MA, Lee HG, Perry G.

Expert Rev Neurother. 2010 Jul;10(7):1201-8. doi: 10.1586/ern.10.74.

[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]

Wouters CJ, Dautzenberg L, Thissen A, Dautzenberg PL.

Tijdschr Gerontol Geriatr. 2010 Jun;41(3):146-50. doi: 10.1007/BF03096196.

Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels

Timmer NM, van Dijk L, van der Zee CE, Kiliaan A, de Waal RM, Verbeek MM.

Neurobiol Dis. 2010 Oct;40(1):340-7. doi: 10.1016/j.nbd.2010.06.008. Epub 2010 Jun 22.

Alzheimer's disease: clinical trials and drug development

Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M.

Lancet Neurol. 2010 Jul;9(7):702-16. doi: 10.1016/S1474-4422(10)70119-8.

Learning from failure

Nat Rev Drug Discov. 2010 Jul;9(7):499. doi: 10.1038/nrd3222.

Animal models of Alzheimer's disease: an understanding of pathology and therapeutic avenues

Obulesu M, Rao DM.

Int J Neurosci. 2010 Aug;120(8):531-7. doi: 10.3109/00207451003760080.

Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease

Bergvall N, Brinck P, Eek D, Gustavsson A, Wimo A, Winblad B, Jönsson L.

Int Psychogeriatr. 2011 Feb;23(1):73-85. doi: 10.1017/S1041610210000785. Epub 2010 Jul 12.

[Effect of compound Polygonum multiflorum extract on Alzheimer's disease]

Chen L, Huang J, Xue L.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Jun;35(6):612-5. doi: 10.3969/j.issn.1672-7347.2010.06.012.

[Animal models of Alzheimer's disease for preclinical research.]

Takahashi H.

Nihon Yakurigaku Zasshi. 2010 Jul;136(1):6-10. doi: 10.1254/fpj.136.6.

[Pharmacological properties of T-817MA, a novel neurotrophic agent, for treatment of Alzheimer's disease.]

Fukushima T.

Nihon Yakurigaku Zasshi. 2010 Jul;136(1):11-4. doi: 10.1254/fpj.136.11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias